Celularity Inc. and Oncternal Therapeutics, Inc. announced they have entered into a research collaboration to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1.
By investigating insulin receptor signaling in human cells and biochemical reconstitution, scientists found that insulin induced the activation of mTORC2 toward AKT by assembling a supercomplex with KRAS4B and RHOA GTPases, termed KARATE (KRAS4B-RHOA-mTORC2 Ensemble).
Towards understanding the underlying molecular alterations that drive pancreatic ductal adenocarcinoma oncogenesis, scientists conducted comprehensive proteogenomic analysis of 140 pancreatic cancers, 67 normal adjacent tissues, and 9 normal pancreatic ductal tissues.
Long non-coding RNAs biological functions and molecular mechanisms associated with pancreatic cancer (PC) remain to be poorly elucidated. Researchers clarified the role of lncRNA LINC00261 in PC and confirmed its regulatory mechanisms.
The authors investigated the transcriptional expressions, methylation level and prognostic value of S100As in pancreatic ductal adenocarcinoma (PDAC) patients from the Oncomine, GEPIA2, Linkedomics and cBioPortal databases. Real-time PCR was used to detect the expressions of S100A2/4/6/10/14/16 in four pancreatic cancer cell lines and pancreatic cancer tissues from PDAC patients undergoing surgery.
Investigators compared normal pancreatic tissues with pancreatic ductal adenocarcinoma (PDAC) tissues according to The Cancer Genome Atlas and clinical samples. Flow cytometry was used to identify M-MDSCs.
Researchers provide an overview on embryonic and putative adult pancreas progenitors in homeostasis and disease, with special emphasis on in vitro culture systems and scRNA-seq technology as tools to address the progenitor nature of different pancreatic cells.
Scientists review the attempts over the past decade, to utilize the organoid cell culture principles in order to identify, expand, and differentiate the adult pancreatic stem cells from different compartments of mouse and human pancreata.
Scientists experimentally verified one such micropeptide encoded by a β cell- and neural cell-enriched lncRNA TCL1 upstream neural differentiation-associated RNA. They provided the first evidence that lncRNA-encoded micropeptides played a critical role in pancreatic β cell functions and provided a foundation for future comprehensive analyses of micropeptide function and pathophysiological impact on diabetes.
Rezolute, Inc. announced that it has begun dosing patients in the second cohort of its Phase IIb clinical trial of RZ358, which is a monoclonal antibody targeting the treatment of hypoglycemia caused by excessive insulin levels and is currently in clinical development for congenital hyperinsulinism, a rare pediatric endocrine disorder.
